ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Metastatic Castration-resistant Prostate Cancer · Metastatic Prostate Cancer · Prostate Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University College London Hospital, London, United Kingdom
Contact: Study coordinator (Trial Manager) · ncita.actinium@ucl.ac.uk

Study leads

Gerhardt Attard
Study Director
University College, London

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)

Breast Cancer · Prostate Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Charlottesville, United States

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Prostate Cancer · Metastatic Castration-resistant Prostate Cancer · mCRPC

Abroad (travel likely)RecruitingPHASE1, PHASE2

Miami, United States · Miami, United States

Prospective Clinical Trial of 177Lu-P17-088 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer

Abroad (travel likely)RecruitingPHASE2

Fuzhou, China

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Boston, United States · Brooklyn, United States